Therapeutic anti-CTLA-4 (clone 9H10) antibody and
isotype control antibody was purchased from BioXcell (cat: BE0131 and BE0087). Antibodies used for flow cytometry were purchased from the following sources (dilutions are indicated in parentheses): eBioscience (
CD45.2 Alexa Fluor 700, cat: 56-0454 (1:200),
CD3 PE-Cy7, cat: 25-0031 (1:200),
CD4 ef450, cat: 48-0041 (1:200), CD4 APC-efluor780, cat: 47-0041 (1:400),
CD8 PerCP-efluor710, cat: 46-0083 (1:200),
CD11b APC-efluor 780, cat: 47-0112 (1:600), ICOS PE, cat: 12-5985 (1:200), ICOSL PE, cat: 12-5985 (1:200),
CTLA-4 PE, cat: 12-1522 (1:200),
NK1.1 PE, cat: 12-5941 (1:200), IFNγ PE, cat: 12-7311 (1:200),
FoxP3 Alexa Fluor 700, cat: 56-5773 (1:100),
FoxP3 APC, cat: 17-5773 (1:200), GATA-3 PE, cat: 12-9966 (1:100), RORγT PerCP-efluor710, cat: 46-6981 (1:100),
Tbet PE-Cy7, cat: 25-5825 (1:100), EOMES efluor 450, cat: 48-4875 (1:100),
PD-1 PE-Cy7, cat: 25-9985, (1:200)), Biolegend (
CD3 BV570, cat: 100225 (1:100), CD11b BV570, cat: 101233 (1:50), Bcl-6 Alexa 594, cat: 648308 (1:50)), Invitrogen (
Granzyme B PE-Texas Red, cat: GRB17 (1:125),
Granzyme B APC, cat: GRB05 (1:125)) and BD Pharmingen (
Ki-67-Alexa Fluor 488, cat: 561165 (1:50), CXCR5-biotin, cat: 551960 (1:100)).
Zamarin D., Holmgaard R.B., Ricca J., Plitt T., Palese P., Sharma P., Merghoub T., Wolchok J.D, & Allison J.P. (2017). Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications, 8, 14340.